Articles
30.11.2022
Reflecting on the Pricing & Market Access tre...

Our experts reflect on the trends that shaped the European pricing and market access landscape in 20...

Read more
Newsletter
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Publications
09.11.2022
ISPOR 2022 Plenary Session 3 - Integrating Data

Our experts provide a detailed summary of Plenary Session 2 at ISPOR 2022 on innovative methods for ...

Read more
Publications
07.11.2022
ISPOR 2022 Plenary Session 1 - HTA and Regulation

Our experts provide a detailed summary of Plenary Session 1 at ISPOR 2022 on the Convergence of HTA ...

Read more
News
02.11.2022
PMA Insights: Week 44

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
Insider Insights
01.11.2022
A winter of discontent? European pharmaceutical so...

EUCOPE and EFPIA have issued a joint statement expressing concerns regarding the implementation of t...

Read more
Newsletter
18.10.2022
PMA Insights: Week 42

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
Insider Insights
18.10.2022
UK Agencies join with International HTA Partners f...

A cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can...

Read more
Articles
12.10.2022
How important is HTA when launching a biosimilar i...

The short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...

Read more
Publications
28.09.2022
ISPOR 2022: Does NICE’s Sta process effectively ...

We investigate Single Technology Appraisals (STAs) conducted by the National Institute for Health an...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.